MW05/LALA
An anti-RBD (SARS-CoV-2 spike protein) recombinant antibody.
General information
MW05/LALA is an antibody modified by mutating its Fc region so that it does not elicit antibody-dependent enhancement. The original antibody was selected based on its affinity to RBD of the SARS-CoV-2 spike protein and was encoded by a memory B-cell of a COVID-19 convalecsent patient (Wang et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Spike protein Biophysical assay Animal model In vitro Antibody |
in vitro biophysical assay; THP-1, K562, and Raji cells (antibody-dependent enhancement analyses); HEK293 cells; Huh7 cells; Vero E6 cells; rhesus macaques | 12.12 | The antibody protected rhesus monkeys from SARS-CoV-2 when administered both in a prophylactic dose (preceding a viral challenge) and in a treatment dose (post-challenge) as assessed by histological and radiological findings and decreased/undetectable viral loads. The antibody did not manifest antibody-dependent enhancement (ADE). The parental antibody (prior to modification in the Fc region to address ADE) bound the SARS-CoV-2 S1 protein (spike) in vitro with Kd below 0.5 nM, inhibited pseudovirus infection in Huh7 cells with fifty percent neutralization titer of 0.03 μg/ml, and provided 100% live virus neutralization in Vero E6 cells at 1 μg/ml. |
Nov/13/2020 |
